<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39423454</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>26</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>17</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Longitudinal safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in children aged 4-11 years with juvenile-onset autoimmune inflammatory rheumatic diseases: A prospective multicenter study.</ArticleTitle><Pagination><StartPage>126426</StartPage><MedlinePgn>126426</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2024.126426</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(24)01108-3</ELocationID><Abstract><AbstractText>This prospective, longitudinal, multicenter study assessed the safety and efficacy of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine among children 4-11 years-old with autoimmune inflammatory rheumatologic disease (AIIRD), compared to healthy controls. The study was conducted from 11/2021-12/2022 at 4 tertiary pediatric rheumatology units in Israel. Participants received at least 2 vaccine doses. Safety analysis included adverse events and disease activity measures. Efficacy was assessed by COVID-19 infection rates. Immunogenicity was evaluated in a subset of participants using anti- receptor binding domain antibody titers. Thirty-one children with AIIRD and 45 immunocompetent controls with similar baseline characteristics were included. Safety profile was favorable, with mild or no adverse events reported. The adverse event rates were similar in the AIIRD and control groups after the first (27 (60 %) vs. 14 (45.2 %), p = 0.2977) and the second vaccine doses (22 (49.0 %) vs. 18 (58.1 %), p = 0.5799), respectively. AIIRD activity remained stable and low after vaccination. Breakthrough COVID-19 infection rates were similar between groups, with 15 (48.4 %) in the AIIRD vs. 25 (55.6 %) in the control group (p = 0.7029). All reported COVID-19 infections in the AIIRD group and 18 (72 %) in the control group were symptomatic (p = 0.033), although symptoms were generally mild, with no severe disease. The safety of the BNT162b2 COVID-19 vaccine was excellent in children ages 4-11 years with AIIRD and healthy controls. Efficacy between groups was similar.</AbstractText><CopyrightInformation>Copyright © 2024. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eviatar</LastName><ForeName>Tali</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Faculty of Medical &amp; Health Sciences, Tel Aviv University, Tel Aviv, Israel. Electronic address: talie@tlvmc.gov.il.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ziv</LastName><ForeName>Amit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medical &amp; Health Sciences, Tel Aviv University, Tel Aviv, Israel; Pediatric Rheumatology Unit, Meir Medical Center, Kfar Saba, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oved</LastName><ForeName>Amir</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Meir Medical Center, Kfar Saba, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller-Barmak</LastName><ForeName>Adi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pediatric Rheumatology Unit, Rambam Medical Center, Haifa, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pappo</LastName><ForeName>Adi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pediatric Rheumatology Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Livny</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Pediatric Rheumatology Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amarilyo</LastName><ForeName>Gil</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Faculty of Medical &amp; Health Sciences, Tel Aviv University, Tel Aviv, Israel; Pediatric Rheumatology Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aviel</LastName><ForeName>Yonatan Butbul</ForeName><Initials>YB</Initials><AffiliationInfo><Affiliation>Pediatric Rheumatology Unit, Rambam Medical Center, Haifa, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naor</LastName><ForeName>Rinat</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pel</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furer</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Faculty of Medical &amp; Health Sciences, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elkayam</LastName><ForeName>Ori</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Faculty of Medical &amp; Health Sciences, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uziel</LastName><ForeName>Yosef</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Faculty of Medical &amp; Health Sciences, Tel Aviv University, Tel Aviv, Israel; Pediatric Rheumatology Unit, Meir Medical Center, Kfar Saba, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heshin-Bekenstein</LastName><ForeName>Merav</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Medical &amp; Health Sciences, Tel Aviv University, Tel Aviv, Israel; Pediatric Rheumatology Service, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biologics</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Children</Keyword><Keyword MajorTopicYN="N">Immunomodulatory medications</Keyword><Keyword MajorTopicYN="N">Juvenile-onset rheumatic diseases</Keyword><Keyword MajorTopicYN="N">Multi-system inflammatory syndrome</Keyword><Keyword MajorTopicYN="N">Pediatric rheumatology</Keyword><Keyword MajorTopicYN="N">Vaccines</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>18</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39423454</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2024.126426</ArticleId><ArticleId IdType="pii">S0264-410X(24)01108-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle>